CUSIP 766559702 · who reports it, how much, and how much it matters to them
12 of the 720 hedge fund managers we track reported shares of Rigel Pharmaceuticals Inc (Nasdaq: RIGL) on Form 13F for 30 June 2026. Between them they reported USD 133m. The largest position belongs to Armistice Capital, at USD 65m. The manager with the most riding on it is CM Management, where it is 6.2% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Armistice Capital1 fund on PPLI.com | USD 65m | 0.8% |
| 2 | D. E. Shaw & Co.15 funds on PPLI.com | USD 21m | 0.0% |
| 3 | Marshall Wace LLP84 funds on PPLI.com | USD 14m | 0.0% |
| 4 | CM Management1 fund on PPLI.com | USD 9.8m | 6.2% |
| 5 | Two Sigma Investments35 funds on PPLI.com | USD 8.1m | 0.0% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 5.7m | 0.0% |
| 7 | Millennium Management6 funds on PPLI.com | USD 3.7m | 0.0% |
| 8 | Squarepoint Ops7 funds on PPLI.com | USD 2.6m | 0.0% |
| 9 | Engineers Gate Manager1 fund on PPLI.com | USD 934,000 | 0.0% |
| 10 | Aquatic Capital Management3 funds on PPLI.com | USD 674,000 | 0.0% |
| 11 | Graham Capital Management18 funds on PPLI.com | USD 471,000 | 0.0% |
| 12 | Persistent Asset Partners10 funds on PPLI.com | USD 228,000 | 0.1% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | CM Management | USD 9.8m | 6.2% |
| 2 | Armistice Capital | USD 65m | 0.8% |
| 3 | Persistent Asset Partners | USD 228,000 | 0.1% |
| 4 | Aquatic Capital Management | USD 674,000 | 0.0% |
| 5 | Engineers Gate Manager | USD 934,000 | 0.0% |
| 6 | Marshall Wace LLP | USD 14m | 0.0% |
| 7 | D. E. Shaw & Co. | USD 21m | 0.0% |
| 8 | Graham Capital Management | USD 471,000 | 0.0% |
| 9 | Renaissance Technologies | USD 5.7m | 0.0% |
| 10 | Two Sigma Investments | USD 8.1m | 0.0% |
Rigel Pharmaceuticals Inc trades under the symbol RIGL on the Nasdaq. Its CUSIP, the code used on Form 13F, is 766559702.
12 of the 720 hedge fund managers PPLI.com tracks reported Rigel Pharmaceuticals Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Armistice Capital (USD 65m), D. E. Shaw & Co. (USD 21m), Marshall Wace LLP (USD 14m), CM Management (USD 9.8m) and Two Sigma Investments (USD 8.1m).
12 managers in our coverage reported it, and between them they run 194 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
CM Management, where the position was 6.2% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Rigel Pharmaceuticals Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.